Bioject Medical Technologies Inc. (BJCT.OB) Receives FDA-Approval to Market its Non-Invasive, Needle-free Technology
Bioject Medical Technologies Inc. (BJCT.OB), developer of needle-free injection therapy systems (NFITS), today announced the U.S. Food and Drug Administration (FDA) has granted market clearance for its Zetajet™ NFITS. The company said the next step is to pursue partnerships to maximize the system’s market introduction. The Zetajet uses jet force to deliver vaccines into subcutaneous or intramuscular tissue, sans needles; the syringe also has a self-powered spring device equipped with an “auto-disable” feature that eliminates reuse of the syringe, making it an attractive option for situations or programs requiring mass immunization. “This new state-of-the-art technology offers features that make this…